Eye Diseases diabetic macula edema,
Conditions
Interventions
intravitreal ziv-aflibercept
intravitreal ziv-aflibercept 1.25mg
Sponsors
Imoro Zeba braimah
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age 18 years or older Meets diagnostic criteria for DM, RVO and active nvAMD (Appendix I) Treatment naïve Understands and willing to sign consent form Able to comply with clinic visits Centre involving ME in patients with diabetes mellitus and RVO with retinal thickness >300um using SD- OCT BCVA of 6/12 or worse
Exclusion criteria
Exclusion criteria: Glaucoma or raised intraocular pressure (>21mmHg) Intraocular surgery within 3 months in the study eye History of uveitis Pregnant or breastfeeding mother Renal failure on dialysis or had kidney transplant Allergy to active drug or excipients Cardiovascular events such as myocardial infarction or CVA Eye infections such blepharitis, dacryocystitis, conjunctivitis or keratitis. Unwilling to sign consent form or to come for follow up visits Myopia ¿-6.0 Dioptres
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety of intravitreal ziv-aflibercept includingincidence of raised intraocular pressure, cataract progression, intraocular inflammation and endophthalmitis | — |
Secondary
| Measure | Time frame |
|---|---|
| ocular and systemic safety parameters, change in BCVA (ETDRS letters), central subfield foveal thickness (CSFT) and central retinal thickness (CRT) using SD-OCT | — |
Countries
Ghana
Contacts
Public ContactBenjamin Abaidoo
Senior research Assistant, School of Medicine and Dentistry, University of Ghana.
Outcome results
None listed